Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study

Takeshi Osonoi,Atsuko Tamasawa,Yusuke Osonoi,Kensuke Ofuchi,Makoto Katoh,Miyoko Saito

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study

2019

Takeshi Osonoi
Atsuko Tamasawa
Yusuke Osonoi
Kensuke Ofuchi
Makoto Katoh
Miyoko Saito

Introduction To investigate canagliflozin-induced changes in postprandial total glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels in patients with type 2 diabetes mellitus (T2DM).

Keywords:

Type 2 Diabetes Mellitus
Internal medicine
Glucosidase Inhibitor
Diabetes mellitus
Peptide
Endocrinology
Postprandial
Medicine
Canagliflozin
Type 2 diabetes
SGLT2 Inhibitor
Glycemic
Metformin
Acarbose

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations